Clinical Trials

77 results for Prostate Cancer


Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial

A Phase II Randomized, Open-Label, Two-Arm Study of a Low-Fat Diet With Fish Oil Capsules vs. a Control Group in Men on Active Surveillance for Prostate Cancer

  • Condition: Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
  • Intervention: Behavioral: behavioral dietary intervention, Behavioral: behavioral dietary intervention, Dietary Supplement: omega-3 fatty acid, Other: laboratory biomarker analysis
  • Study ID: NCT02176902
View Trial

Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: Rucaparib
  • Study ID: NCT03413995
View Trial

Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial

  • Condition: Prostate Cancer
  • Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
  • Study ID: NCT03482089
View Trial

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)

  • Condition: Prostate Cancer
  • Intervention: Drug: Rucaparib
  • Study ID: NCT03533946
View Trial

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Can
  • Intervention: Drug: Abiraterone Acetate, Drug: Antiandrogen Therapy, Drug: Cabazitaxel, Other: Laboratory Biomarker Analysis, Procedure: Orchiectomy, Other: Pharmacological Study, Drug: Prednisone
  • Study ID: NCT03419234
View Trial

Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study

  • Condition: Prostate Cancer, Bone Metastases
  • Intervention: Drug: Zoledronic Acid, Drug: Enzalutamide
  • Study ID: NCT03336983
View Trial

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Drug: Leuprolide Acetate, Drug: Goserelin Acetate, Radiation: Stereotactic Body Radiation Therapy, Radiation: Radium Ra 223 Dichloride, Other: Laboratory Biomarker Analysis
  • Study ID: NCT03361735
View Trial

Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer

  • Condition: Prostate Cancer, Adenocarcinoma of the Prostate
  • Intervention: Drug: Nivolumab, Drug: Degarelix, Drug: BMS-986253
  • Study ID: NCT03689699
View Trial

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

  • Condition: Prostate Cancer, Localized Malignant Neoplasm
  • Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT01766492
View Trial

A Randomized Clinical Trial of Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer

  • Condition: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
  • Intervention: Behavioral: Exercise
  • Study ID: NCT02435472
View Trial

A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

  • Condition: Prostate Cancer
  • Intervention: Drug: Olaparib, Drug: Durvalumab
  • Study ID: NCT03810105
View Trial

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes

  • Condition: Prostate Cancer, Adenocarcinoma of the Prostate
  • Intervention: Drug: Olaparib Pill, Procedure: Prostatectomy
  • Study ID: NCT03432897
View Trial

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

  • Condition: Stage II Prostate Adenocarcinoma
  • Intervention: Radiation: Intensity-Modulated Radiation Therapy (IMRT), Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT03367702
View Trial

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

  • Condition: Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Pro
  • Intervention: Drug: Carboplatin, Drug: Cisplatin, Drug: Docetaxel, Drug: Etoposide, Biological: Pembrolizumab
  • Study ID: NCT03582475
View Trial

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
  • Study ID: NCT03753243
View Trial

A Phase 1/2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Ibrutinib
  • Study ID: NCT02643667
View Trial

Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
  • Study ID: NCT03568188
View Trial

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Combination Product: MVA-BN-Brachyury
  • Study ID: NCT04020094
View Trial

A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer

  • Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
  • Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
  • Study ID: NCT04253483
View Trial

Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-guided Transurethral Ultrasound Ablation for Localized Prostate Cancer

  • Condition: Localized Prostate Cancer
  • Intervention: Device: MRI-TULSA
  • Study ID: NCT03814252
View Trial

Hypofractionated Radiosurgery for Localised Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Hypofractionated Radiosurgery
  • Study ID: NCT03795337
View Trial

SAABR: Single-Arm Phase II Study of Abiraterone Acetate + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: Atezolizumab, Drug: Abiraterone, Drug: Prednisone, Drug: Lupron, Radiation: Stereotactic Body Radiotherapy (SBRT)
  • Study ID: NCT04262154
View Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT), Drug: Placebo
  • Study ID: NCT03767244
View Trial

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
  • Study ID: NCT03531099
View Trial

68GA-PSMA FUSION PET/MRI FOR IMAGE-GUIDED PROSTATE BIOPSIES

  • Condition: Prostate Cancer
  • Intervention: Drug: 68Ga-PSMA
  • Study ID: NCT03689582
View Trial

A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Study ID: NCT04332744
View Trial